Effect of Antihistamines on Ureteral Stent-Related Symptoms
Status:
Recruiting
Trial end date:
2022-03-01
Target enrollment:
Participant gender:
Summary
This is a prospective, double-blind, randomized, open-label, single-center trial of up to 78
participants who are adult patients (aged 18-80 years) and are undergoing unilateral
retrograde ureteroscopy with planned ureteral stent placement for treatment of urinary tract
stones. Eligible patients will be randomly and divided into two groups in a 1:1 ratio. Group
A will receive fexofenadine 180 mg once daily in addition to standard of care treatment.
Group B will receive placebo in addition to standard of care treatment. The routine standard
of care treatment will consist of oral non-steroidal anti-inflammatory drugs (NSAIDs).
The primary outcomes of the study are the Ureteral Stent Symptom Questionnaire (USSQ) urinary
symptom score and pain score. Secondary outcomes include (i) number of office phone calls due
to urinary symptoms; (ii) duration of analgesic use; (iii) duration and quantity of narcotic
use; (iv) number of emergency department visits; (v) drug-related adverse effects; (vi) other
domains of the USSQ.